Key result
The Thr21Met polymorphism of the UTS2 gene was significantly associated with the risk of developing systemic sclerosis, with the M21M genotype being less frequent in patients than controls (OR 0.295).
Why the study?
Are Urotensin II gene polymorphisms (Thr21Met and Ser89Asn) associated with the risk of developing systemic sclerosis?
Case-Control (n=394)
Single-blind
Yes
Are Urotensin II gene polymorphisms (Thr21Met and Ser89Asn) associated with the risk of developing systemic sclerosis?
The Thr21Met polymorphism in the Urotensin II gene is a significant risk factor for developing systemic sclerosis and is associated with severe skin and lung involvement.
Answers are grounded in this paper and cite their sources.
UTS2 Thr21Met variant was associated with lower systemic sclerosis risk; hypothesis-generating and requires independent replication before any clinical consideration.
OBJECTIVE: Systemic sclerosis (SSc) is an autoimmune chronic fibrotic disorder. Urotensin II (U-II) is predominantly a vasoactive peptide with fibrotic and prothrombotic features. Like endothelin-1 (ET-1), U-II could play an important role in SSc pathogenesis. We evaluated the possible role of the U-II gene polymorphisms (Thr21Met and Ser89Asn) in the genetic susceptibility to SSc in a Turkish population. METHODS: A total of 189 patients with SSc and 205 healthy controls were enrolled in our study. We analyzed the genotype and allele frequencies of the U-II (UTS2) gene polymorphisms Thr21Met and Ser89Asn in patients with SSc and in controls. RESULTS: We found that the Thr21Met polymorphism of the UTS2 gene was markedly associated with the risk of developing SSc (p < 0.0001), but there was no relationship between the Ser89Asn polymorphism and SSc (p > 0.05). Two haplotypes (MS and TS) were markedly associated with SSc (p < 0.05). There were significant associations between the genotype and allele frequencies of UTS2 gene Thr21Met polymorphism and cases with diffuse or limited SSc, systemic or lung involvement, finger flexion deformity, pitting scars at the fingertips, positive anticentromere, or positive antitopoisomerase 1 antibody groups. CONCLUSION: Our study shows the association between Thr21Met, but not Ser89Asn, in the UTS2 gene and SSc. The results strongly suggest that this single-nucleotide polymorphism may be an important risk factor in the development of SSc, and a powerful indicator of severe skin and lung involvement in patients with SSc.
No takes yet. Share an insight, caveat, or question.
Pehlivan et al. (2011) conducted a case-control in Systemic Sclerosis (n=394). UTS2 gene Thr21Met polymorphism vs. Healthy controls was evaluated on Association of the M21M genotype of the UTS2 gene with systemic sclerosis (OR 0.295, 95% CI 0.161-0.539, p=<0.0001). The Thr21Met polymorphism of the UTS2 gene was significantly associated with the risk of developing systemic sclerosis, with the M21M genotype being less frequent in patients than controls (OR 0.295).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: